Drug delivery systems of gefitinib for improved cancer therapy: A review
Author:
Publisher
Elsevier BV
Subject
Pharmacology (medical),Pharmaceutical Science,Biotechnology,Internal Medicine
Reference91 articles.
1. Lifestyle as risk factor for cancer: Evidence from human studies;Khan;Cancer Lett.,2010
2. Transformation from non-small-cell lung cancer to small-cell lung cancer: molecular drivers and cells of origin;Oser;Lancet Oncol.,2015
3. New target therapies in advanced non-small cell lung cancer: a review of the literature and future perspectives;De Mello;J. Clin. Med.,2020
4. EML4-ALK: honing in on a new target in non–small-cell lung cancer;Horn;J. Clin. Oncol.,2009
5. Approval summary for erlotinib for treatment of patients with locally advanced or metastatic non–small cell lung cancer after failure of at least one prior chemotherapy regimen;Johnson;Clin. Cancer Res.,2005
Cited by 2 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献
1. On chip synthesis of a pH sensitive gefitinib anticancer drug nanocarrier based on chitosan/alginate natural polymers;Scientific Reports;2024-01-08
2. Synergistic Phototherapy-Molecular Targeted Therapy Combined with Tumor Exosome Nanoparticles for Oral Squamous Cell Carcinoma Treatment;Pharmaceutics;2023-12-26
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3